Non-alcoholic fatty liver disease (NAFLD), the leading cause of chronic liver disease in
Western countries, has been identified as a possible risk factor for COVID-19 severity …

Non-alcoholic fatty liver disease (NAFLD) is identified as a risk factor for developing severe
COVID-19. While NAFLD is associated with chronic low-grade inflammation, mechanisms …

This study aims to evaluate the effect of non‐alcoholic fatty liver disease (NAFLD) on the
susceptibility and consequences of coronavirus disease 2019 (COVID‐19). We …

Background & Aims The coronavirus disease 2019 (COVID-19) pandemic has witnessed
more than 4.5 million deaths as of the time of writing. Whether nonalcoholic fatty liver …

For targeted intervention in coronavirus disease 2019 (COVID‐19), there is a high medical
need for biomarkers that predict disease progression and severity in the first days after …

Aim Coronavirus disease 2019 (COVID-19) is a recently encountered disease that was
declared a pandemic by WHO in 2020. Obesity and other components of the metabolic …

Abstract Background Initial evidence from China suggests that most vulnerable subjects to
COVID‐19 infection suffer from pre‐existing illness, including metabolic abnormalities. The …

During the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, particular
interest rose regarding the interaction between metabolic dysfunction-associated fatty liver …

Background Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease
associated with systemic changes in immune response, which might be associated with …

A recent study reported that patients with severe COVID-19 were more likely to have non-
alcoholic fatty liver disease (NAFLD) compared with those with non-severe COVID-19 …